Probi has now taken over North America distribution after Blis Technologies ended its distribution deal with a previous partner.
Probiotics supplier Probi AB (Lund, Sweden) has now taken over distribution of the trademarked oral-health probiotic ingredients BLIS K12 and BLIS M18 in North America. Probi has had a distribution partnership with Blis Technologies, the maker of BLIS probiotic strains, since July 2021. Recently, Blis Technologies ended a distribution agreement with a previous partner, making Probi the sole distributor of BLIS K12 and BLIS M18 in the U.S. and Canada.
“Probi has also completed the technology transfer for the full production of dairy-free BLIS K12 and BLIS M18 in their manufacturing facility in Redmond, WA, which means that Probi has full-scale production capacity of both bulk powder and product applications of the strains,” the companies’ press release states.
“Oral health is a growing niche in probiotics,” added Diane Alexander, North America sales director at Probi AB. “We will be alone in the U.S. with dairy-free oral probiotics, and we see great growth potential of the BLIS strains. Our ability to offer customers both bulk powder and customized applications provides differentiated solutions to meet consumer demand.”
The press release adds: “Streptococcus salivarius BLIS K12 and Streptococcus salivarius BLIS M18 are part of a portfolio of clinically documented bacterial strains for supporting our natural immune defense and preventing infections of the mouth and throat. The BLIS strains also contribute to a healthy set of teeth and gums. Blis Technologies’ clinically documented strains have a successful history of use in New Zealand, Australia, and Asia, as well as in Europe and in North America.”